AbCellera Biologics Earning Date (ABCL)

USA |NASDAQ |USD

ABCL Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Mar 29, 2022 (est) Dec 31, 2021 - - $0.37
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Mar 29, 2022 (est) Dec 31, 2021 - - $207.91M

Abcellera Biologics's next estimated earnings date (based on same quarter last year's date) is Mar 29, 2022 for the fiscal quarter ending Dec 31, 2021.

ABCL Earnings Date & History Chart

ABCL Earnings & Revenue Forecast

ABCL Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 4 $0.02 $-0.10 $0.19
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 5 $0.37 $0.17 $0.52
Dec 2022 5 $-0.14 $-0.37 $0.16

ABCL Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $-0.03 $-0.05 $-0.02
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2021 1 / 0 $0.37 $0.33 $0.57
Dec 2022 0 / 1 $-0.01 $-0.17 $0.00

ABCL Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Dec 2021 4 $47.07M $4.74M $126.73M
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2021 5 $284.44M $244.12M $364.70M
Dec 2022 5 $119.56M $40.26M $259.02M

ABCL Earnings Date & Revenue History

ABCL Earnings History

|
Show More
Show More

ABCL Revenue History

|
Show More
Show More

Abcellera Biologics Next Earnings Date & Report

ABCL Nov 2021 (FQ) Earnings Date & Report Preview

ABCL's next estimated earnings date (based on same quarter last year's report date) is Mar 29, 2022 for the fiscal quarter ending Dec 31, 2021.

Abcellera Biologics Previous Earnings Dates & Reports

ABCL Previous Earnings Date & Report Recap: Sep 2021 (FQ)

Abcellera Biologics's previous earnings date was Nov 9, 2021 for its fiscal quarter ended Sep 30, 2021.

ABCL Previous Earnings Date & Report Recap: Dec 2020 (FY)

Abcellera Biologics's previous annual earnings date was Mar 29, 2021 for its fiscal year ended Dec 31, 2020.

ABCL's earnings per share (EPS) was $0.35, missing the consensus analysts forecast of $0.60 by -41.78% , and higher than the previous year's EPS (Dec 2019) by -14654.17%.

Revenues were $233.16M, better than the forecast of $212.90M by 9.51%, and up by 1907.96% from previous year's revenue.

The company reported a net income of $118.92M.

Abcellera Biologics reported a free cash flow of $8.02M for its fiscal year, compared to $-1.30M a year ago.

The company ended the fiscal year with $3.06M in total debt, a decrease of -27.92% compared to the previous year.